1、 2025.All rights reserved.IQVIA is a registered trademark of IQVIA Inc.in the United States,the European Union,and various other countries.Thirty-Seventh EditionMiddle East&AfricaPharmaceutical Business InsightsReport Release Date:Sep 2025Analytical Timeframe:MAT Jun 20251DisclaimerIQVIA is not an“a

2、uthorised person”for the purposes of the Financial Services and Markets Act 2000(“FSMA”)and does not provide investment advice or carry on any other regulated activity under Part II of the FSMA 2000(Regulated Activities)Order 2001The forecasts,projections,and related information contained herein are

3、 made and provided subject to the assumptions,methodologies,caveats,and variables described in this report and are based on third party sources and data reasonably believed to be reliable.No warranty is made as to the completeness or accuracy of such third party sources or dataThis report,in part or

4、 in whole,is not intended to constitute investment advice,and is not a recommendation to purchase or not purchase,an endorsement of,or an opinion as to the value of,any security or any investment instrument of any entityAs with any attempt to estimate future events,the forecasts,projections,conclusi

5、ons,and other information included herein are subject to certain risks and uncertainties,and are not to be considered guarantees of any particular outcomeThis report shall not be published,nor shall any public references to IQVIA be made regarding these services or this report,without IQVIA prior wr

6、itten approval.When so provided,this report and the information herein must always be provided and used in its entirety,including this complete Disclaimer pageThis report is subject to the IQVIA General Terms and Conditions.2+Newsletter report summary+Regional summary and analysis+Spotlight on new o